Raymond Debbane
@Siren, L.l.c.
Latest period2024 - Q3ReportedManaged Assets$2BTotal holdings110
Assets growth rate0%Assets growth rate (2-Q avg)0%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Siren, L.l.c.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 110 positions.
Assets under management
The assets under management (AUM) of Siren, L.l.c. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 2B in assets, with a quarterly growth rate of 0% and a 2-quarter average growth rate of 0%. The portfolio is managed by Raymond Debbane, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
CNTACentessa Pharmaceuticals Plc
| 2.61% | $52.106M 3.259M shares@ $15.99 avg price | New Position |
ASNDAscendis Pharma A S
| 2.6% | $51.948M 347,921 shares@ $149.32 avg price | New Position |
SLNSilence Therapeutics Plc
| 2.58% | $51.482M 2.832M shares@ $18.19 avg price | New Position |
ARWRArrowhead Pharmaceuticals Inc
| 2.39% | $47.627M 2.459M shares@ $19.38 avg price | New Position |
WVEWave Life Sciences Ltd
| 2.35% | $46.914M 5.721M shares@ $8.2 avg price | New Position |
SWTXSpringworks Therapeutics Inc
| 2.21% | $44.142M 1.378M shares@ $32.04 avg price | New Position |
DYNDyne Therapeutics Inc
| 2.04% | $40.757M 1.135M shares@ $35.93 avg price | New Position |
VERAVera Therapeutics Inc
| 1.86% | $37.036M 837,928 shares@ $44.21 avg price | New Position |
NMRANeumora Therapeutics Inc
| 1.73% | $34.433M 2.607M shares@ $13.22 avg price | New Position |
PCVXVaxcyte Inc
| 1.72% | $34.28M 299,991 shares@ $114.28 avg price | New Position |